It is well-known that aPL antibodies might be persistently present in the serum of APS patients for long periods of time, but thrombotic events only occur occasionally. It has been suggested that ...

and anti-β 2 glycoprotein-I antibodies) Enroll patients with specific laboratory features of APS confirmed in core labs Enroll patients with specific clinical features of APS Compare efficacy of ...

Mortality among persistently aPL-positive patients was associated with arterial thrombosis, concomitant systemic autoimmune diseases, and CVD risk factors.

Antiphospholipid antibody syndrome (APS) is a rare autoimmune condition that causes thickening of the circulating blood. APS is estimated to affect one in 2,000 people in the United States alone.

ADCE-T02 is a potential first-in-class Topoisomerase I inhibitor-based antibody-drug conjugate (ADC) targeting tissue factor, a validated ADC target overexpressed in multiple solid tumors Phase I ...

antiphospholipid antibodies; APS, antiphospholipid syndrome; ELISA, enzyme-linked immunosorbent assay. On the basis of a limited number of studies that predominantly included patients with ...

ADCE-T02 is a potential first-in-class Topoisomerase I inhibitor-based antibody-drug conjugate (ADC ... rates and longer duration of Adcendo ApS is a clinical-stage biotechnology company ...